Back

Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial). a phase III study

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Ventricular arrhythmias and sudden cardiac death e-posters Drug Treatment of Ventricular Arrhythmias ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Associate Professor Dirk von Lewinski

Medical University of Graz, Graz (Austria)

38 More presentations in this session

Presentation thumbnail
A territory-wide study of arrhythmogenic right ventricular cardiomyopathy patients from Hong Kong
Mr I. Lakhani (Hong Kong, CN)
Abstract Slides
Presentation thumbnail
Arrhythmias caused by mutations in SCN5A in children
Miss E. Polyakova (Moscow, RU)
Abstract Slides
Presentation thumbnail
Real-world evaluation of follow up strategies after implantable cardiac-defibrillator therapies in patients with ventricular tachycardia (REFINE-VT)
Doctor P. Tran (Coventry, GB)
Abstract Slides
Presentation thumbnail
Sex differences in incidence of out-of-hospital cardiac arrest across ethnic and socioeconomic groups: a population-based cohort study in the Netherlands
Ms R. Bolijn (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Socioeconomic data predict adverse cardiovascular outcomes
Professor J. Kostis (New Brunswick, US)
Abstract Slides

Access the full session

Session thumbnail
Ventricular arrhythmias and sudden cardiac death e-posters

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Effect of dapagliflozin on ventricular arrhythmic events in heart failure patients with implantable defibrillator.
12 May 2024
thumbnail
Congress Presentation
ERASe - Ertugliflozin to Reduce Arrhythmic burden in ICD/CRT patientS
1 September 2024
thumbnail
Congress Presentation
Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk of cardiovascular and renal disease among type 2 diabetes patients in routine care in europe and israel: EMPRISE study results
29 June 2021
thumbnail
Congress Presentation
SGLT2i uptake among heart failure patients with reduced ejection fraction: ongoing prescriber hesitancy and how to address this.
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources